Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–3 of 3 results
Advanced filters: Author: "Alan Thompson" Clear advanced filters

  • The application of imaging biomarkers has provided new insights into the mechanisms of damage in multiple sclerosis (MS) and the risk of MS development and progression. The goal of eliminating all disease activity requires a timely escalation of treatment. This increasing complexity is compounded by the need to treat comorbidities.

    • Olga Ciccarelli
    • Alan Thompson
    News & Views
    Nature Reviews Neurology
    Volume: 12, P: 70-72

  • Following extensive progress in the treatment of relapsing multiple sclerosis, the major challenge in the field is now to develop effective therapies for progressive forms of multiple sclerosis. As the first signs of success emerge, now is the time to consider the research needed to move the field forward.

    • Alan Thompson
    • Olga Ciccarelli
    Comments & Opinion
    Nature Reviews Neurology
    Volume: 16, P: 589-590

  • The treatment of multiple sclerosis (MS) has evolved remarkably over the past 25 years. This progress has been enabled by advances in research, drug development and active engagement of the scientific community with regulatory authorities. However, an inconsistent approach to MS disease courses could have a negative impact on the drug development process.

    • Timothy Coetzee
    • Alan J. Thompson
    Comments & Opinion
    Nature Reviews Neurology
    Volume: 14, P: 191-192